Compare NUVL & SPXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | SPXC |
|---|---|---|
| Founded | 2017 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 10.1B |
| IPO Year | 2021 | 1994 |
| Metric | NUVL | SPXC |
|---|---|---|
| Price | $123.60 | $232.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | $134.75 | ★ $245.56 |
| AVG Volume (30 Days) | ★ 4.2M | 673.5K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | N/A | ★ 1.19 |
| Revenue | N/A | ★ $2,265,100,000.00 |
| Revenue This Year | N/A | $16.07 |
| Revenue Next Year | $1,239.49 | $7.68 |
| P/E Ratio | ★ N/A | $206.11 |
| Revenue Growth | N/A | ★ 14.17 |
| 52 Week Low | $71.14 | $169.18 |
| 52 Week High | $123.69 | $251.08 |
| Indicator | NUVL | SPXC |
|---|---|---|
| Relative Strength Index (RSI) | 66.56 | 50.92 |
| Support Level | $98.56 | $187.90 |
| Resistance Level | $123.62 | $245.66 |
| Average True Range (ATR) | 0.21 | 10.74 |
| MACD | -0.05 | -0.79 |
| Stochastic Oscillator | 82.41 | 41.88 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company operates through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The Detection and Measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others. It derives maximum revenue from United States.